10/536950

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV520562542US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 31, 2005

Signature: (Many Jane Dipalma)

JCO6 Rec's PCT/PTO 31 MAY 2005

Docket No.: DFMP-P01-480

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Herget et al.

Application No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: May 31, 2005

Art Unit: Not Yet Assigned

For:

FORMULATIONS USEFUL AGAINST

HEPATITIS C VIRUS INFECTIONS

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided because they were previously cited by or submitted to the Office in a prior application number PCT/EP2003/013514, filed December 1, 2003 and relied upon in this application. A copy of the International Search Report for PCT/EP2003/013514 is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: Not yet Assigned

Docket No.: DFMP-P01-480

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. DFMP-P01-480.

Dated: May 31, 2005

Respectfully submitted,

David P. Halstead, Ph.D.

Registration No.: 44,735

**ROPES & GRAY LLP** One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	Not ye Assigned 6 9 5 U	
11	<b>NFORMATION</b>	1 DI	SCLOSURE	Filing Date	May 31, 2005	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Thomas Herget	
				Art Unit	Not Yet Assigned	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	DFMP-P01-480	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( ii known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Γ		
Initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				T⁵		
	ВА	DE-36 10 531 A	10-16-1986			П		
	BB	DE-199 36 672 A	02-15-2001			Г		
	ВС	DE-43 20 878 A	01-26-1995					
	BD	EP-1 046 399 A	10-25-2000					
	BE	WO-02/066022 A	08-29-2002					
	BF	WO-02/32413 A	04-25-2002					
	BG	WO-01/037032 A1	11-01-2001					
	ВН	WO-97/03682 A	02-06-1997					
	ВІ	WO-02/084294 A	10-24-2002	-				
	BJ	WO-03/180719 A1	09-25-2003					
	BK	WO-97/13505 A	04-17-1997					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		Look et al., "Interferon/antioxidant combination therapy for chronic hepatitis C-A controlled pilot trial," Antiviral Research 43(2):113-122 (1999)			
	CB	PCT/EP2003/013514 International Search Report 09/10/2001			

<sup>\*</sup>EXAMINER: Initia! if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.